Corporate Overview. July 2016 NASDAQ: CYTR
|
|
- Zoe Bridges
- 6 years ago
- Views:
Transcription
1 Corporate Overview July 2016 NASDAQ: CYTR
2 CytRx Safe Harbor Statement THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE CERTAIN RISKS AND UNCERTAINTIES ASSOCIATED WITH A DEVELOPMENT-STAGE COMPANY. ACTUAL RESULTS COULD DIFFER MATERIALLY FROM THOSE PROJECTED IN THE FORWARD-LOOKING STATEMENTS AS A RESULT OF THE RISK FACTORS DISCUSSED IN CYTRX REPORTS ON FILE WITH THE U.S. SECURITIES AND EXCHANGE COMMISSION INCLUDING, BUT NOT LIMITED TO, THE REPORT ON FORM 10-K FOR THE YEAR ENDED DECEMBER 31, 2015, AND FORM 10-Q FOR THE QUARTER ENDED MARCH 31,
3 CytRx Investment Highlights Proprietary Drug Generation Platform: LADR TM (Linker-Activated Drug Release) Technology Concentrates drug release at the tumor, minimizing systemic exposure and allowing for higher doses and additional cycles Improves efficacy and side-effect profiles of known chemotherapy drugs Late-stage, technology-validating lead drug candidate Aldoxorubicin pivotal Ph 3 (SPA) on-going in 2 nd -line soft tissue sarcoma (STS) Phase 3 PFS data expected in July 2016 Potential for first FDA approval in 2017 Wholly-owned by CytRx Attractive Market Opportunity Potential to be a key therapy for treating STS Orphan drug designations in US & EU Indication expansion where doxorubicin is ineffective like SCLC, GBM Pipeline Potential Substantial in-house chemistry expertise to create new drug conjugates DK049 selected for clinical development IND filing planned for
4 LADR: Linker Activated Drug Release Targeting Ability Localization of drug at tumor using albumin, antibodies, etc. Cleavable Linker Chemistries for controlled release of drug either extra- or intra-cellularly Drug Payload Anti-cancer drugs, high potency cytotoxic agents Albumin transports drug to the tumor and is taken up by the tumor Linker covalently binds within minutes to serum albumin Tumor cells cells Linker dissolves in the acidic environment, releasing the drug payload Cancer Drug Shortcomings LADR TM Technology Potential Advantages Limited therapeutic index Prolonged drug exposure Off-target toxic effects Allows drug to accumulate in the tumor Linker structure prevents release in healthy cells Lack of efficacy Ability to delivery standard and high potency drug payloads Drug Resistance LADR TM conjugates can evade traditional drug resistance mechanism 3
5 Aldoxorubicin: A First-in-Class, Targeted Anthracycline Using LADR TM Technology Phase 3 pivotal trial in STS is fully enrolled Top-line data expected in July 2016 Superior efficacy to doxorubicin in comparative trial Ability to administer 3.5x more doxorubicin equivalents at each cycle Can treat beyond doxorubicin s black box dose limit No clinically significant cardiotoxicity to date Patients have received up to 12x more cumulative anthracycline with aldoxorubicin than possible with doxorubicin Over 550 patients treated with aldoxorubicin to date Orphan drug status granted USA: STS, small cell lung cancer, GBM, pancreatic & ovarian cancers Europe: STS 4
6 CytRx Pipeline Aldoxorubicin 2 nd -Line Soft Tissue Sarcoma 2 nd -Line Small Cell Lung Cancer Glioblastoma Multiforme Kaposi s Sarcoma Combo with gemcitabine Combo with ifosfamide Preclinical Phase 1 Phase 2 Phase 3 Phase 3 Pivotal Trial Top-line data in July 2016 Phase 2b on-going Phase 2 on-going Enrollment Complete Phase 2 Enrollment Complete Ph 1b on-going Ph 1b on-going DK049 IND planned for
7 Soft Tissue Sarcoma (STS) Cancer of the soft, connective tissue Affects muscle, fat, blood vessels, nerves, tendons and the lining of joints (synovial tissues) More than 50 different sub-types Growing, underserved target market Approximately 40,000 new cases in the U.S. and Europe annually More than 13,000 deaths annually Significant unmet medical need Doxorubicin is the standard of care All patients progress on existing therapies 10% Head and Neck 15% GI Tract 15% Retroperitoneum/ Intra-abdominal 60% Arms or Legs 6
8 Why Soft Tissue Sarcomas? It is a model tumor to establish proof of concept (POC) Single-agent doxorubicin is approved as 1 st -line therapy for STS 1 st -line STS provided setting for head-to-head Phase 2b trial comparing aldoxorubicin to doxorubicin Superior efficacy to doxorubicin in comparative trial Why 2 nd -line STS for the Phase 3 Pivotal Trial? Significant unmet medical need: no standard of care for patients PFS is acceptable primary endpoint Clinical data to support aldoxorubicin activity in 2 nd -line STS patients 1 st -line STS had competing trials 7
9 Phase 2b STS Trial: PFS Results All Subjects Intent-to-treat P Value Scans Read by Investigator Aldoxorubicin Doxorubicin 8.3 months 4.6 months P= Improvement over dox 3.7 mos. (80%) Hazard ratio 0.44 ( ) P= Scans Read by Central Lab Aldoxorubicin Doxorubicin 5.6 months 2.7 months P= Improvement over dox 2.9 mos. (107%) Hazard ratio 0.60 ( ) P= Results published in JAMA Oncology in September
10 PFS Comparison to Recent STS Trials Single agent aldoxorubicin achieved superior PFS to combination therapies Aldox - Investigator Aldox- central lab Aldoxorubicin Max of 6 cycles Dox+Ifos 7.4 Dox+TH-302 Dox+Olaratumab PFS Dox PFS Dox+Pali Ph Trabectedin Months Last treatment Cycle 6 (21 day cycle) TH-302 and olaratumab treatment continued until disease progression; doxorubicin stopped after six cycles 9
11 Waterfall Plot - Investigator Aldoxorubicin 64.5% had tumor shrinkage Doxorubicin 41.2% had tumor shrinkage JAMA Oncology2015 Dec;1(9):
12 Waterfall Plot Blinded Central Lab Aldoxorubicin 60.8% had tumor shrinkage Doxorubicin 39.4% had tumor shrinkage JAMA Oncology2015 Dec;1(9):
13 Phase 2b: Safety Data Adverse events were consistent with known doxorubicin toxicities Certain grade 3 or 4 AEs such as neutropenia, mucositis, nausea/vomiting and leukopenia, were higher in aldoxorubicintreated subjects but were not treatment limiting Aldoxorubicin treated subjects had no evidence of clinically relevant decreased left ventricular ejection fraction (LVEF) ~9% of doxorubicin treated patients had clinically significant cardiotoxicity 12
14 2 nd -Line STS: No Standard of Care Dacarbazine Phase 3 comparators Gemcitabine & Docetaxel Ifosfamide Doxorubicin Aldoxorubicin Potential to become the standard of care for treating relapsed and/or refractory patients with soft tissue sarcoma Pazopanib Excludes liposarcoma Trabectedin Liposarcoma and Leiomyosarcoma only Eribulin Liposarcoma only 13
15 Phase 3 Pivotal Trial in 2 nd -Line STS Randomized, Comparative Trial Design with SPA Special Protocol Assessment (SPA) granted by FDA Protocol allows for dosing until disease progression Patient Population 433 STS patients that have progressed following treatment with chemotherapy Up to 5 prior cycles or 375mg/m 2 of doxorubicin or liposomal doxorubicin equivalents allowed Endpoints Primary: Progression Free Survival Secondary: Overall survival, response rates, safety, etc. 14
16 Phase 3 Trial Design: 2 nd -line STS Trial is currently on-going 79 sites located in the USA, Canada, Europe, Israel, Australia and Chile Timing Achieved 191 events in April 2016 triggering the data analysis of the primary endpoint of PFS Enrollment completed ahead of schedule in Q415 PFS data expected to be available July 2016 Projected NDA filing at end of 2016 Commercial launch in 2017 Soft tissue sarcoma patients that have relapsed or are refractory to prior chemotherapy 1:1 Randomization N=400 Aldoxorubicin 350mg/m 2 (260mg/m 2 dox equiv.) Every 3weeks until disease progression N=200 Physicians Choice: Doxorubicin Ifosfamide Dacarbazine Pazopanib Gemcitabine+ docetaxel N=200 CT Scans every 6 weeks 15
17 Beyond STS: Indication Expansion Small Cell Lung Cancer ~15% of all lung cancers Poor prognosis; topotecan is the only approved 2 nd -line drug Randomized Phase 2b 132 patient trial is enrolling comparing aldoxorubicin to topotecan in 2 nd -line SCLC Glioblastoma Stage IV brain cancer Poor prognosis; doxorubicin does not cross the blood-brain barrier (BBB) Preclinical and clinical data suggest aldoxorubicin crosses the BBB and has anti-cancer activity Updated data presented at ASCO
18 ASCO Update Phase 2 Glioblastoma First demonstration of an albumin-binding therapy entering the brain and having anti-tumor activity Median OS of 8.6 months 7 patients still being followed Baseline Week 6 Phase 2 Kaposi s Sarcoma 15 patients received low dose aldoxorubicin 11 of 13 (85%) had partial responses at week 4 Very well tolerated by late stage patients Higher doxorubicin concentrations detected in KS lesions compared to nontumor tissues Phase 1b Trial of Aldoxorubicin + Gemcitabine Able to administer combo to heavily pretreated patients (range 1-15 prior regimens) 11 of 13 (85%) had partial responses or stable disease Final cohort still ongoing Baseline Cycle 2 17
19 DK049: Novel LADR TM -Enhanced Gemcitabine Derivative Advantages over gemcitabine After infusion, binds albumin for transport and accumulation at the tumor Dual releasing linker for prolonged release of the active drug at the tumor site Gemcitabine DK049 Targeted to the tumor No Yes via albumin Deactivated by cytidine deaminase >90% No hent1 transporter dependent Yes No Half-life Short Long Pre-clinical activity in multiple models including non-small cell lung, pancreatic, and ovarian cancers 13-fold greater anti-tumor activity with 85% less drug than comparator Data presented at the American Association for Cancer Research (AACR) Annual Meeting in April
20 DK049: Non-Small Cell Lung Cancer Absolute Tumor Volume [mm3] LXFE 937 xenograft model Control Vehicle Gemcitabine 4 x 240 mg/kg DK049 8 x 18 mg/kg p < 0.05 vs. gemcitabine Days after Randomization 19
21 DK049: Ovarian Cancer 2500 OVXF 899 xenograft model Absolute Tumor Volume [mm3] Starting tumor volume 200 mm 3 Control Vehicle Gemcitabine 4 x 240 mg/kg DK049 8 x 18 mg/kg p < 0.05 vs. gemcitabine Days after Randomization 20
22 Expected Upcoming Catalysts Q16: Enrollment in Phase 3 STS trial - Completed ahead of schedule in Q : NDA approval for aldoxorubicin in STS 2Q16: Present data on DK049 at the AACR Annual Meeting in April 2017: Commercial launch of aldoxorubicin for soft tissue sarcoma 2Q16: Present clinical trial updates at ASCO on GBM, Kaposi s sarcoma and gemcitabine combination with aldoxorubicin July 2016: Phase 3 STS PFS data 2017: DK049 Phase 1 results 2017: Initiate Phase 1 trial with next drug-conjugate 2H16: GBM OS data 2H16: Begin NDA filing in STS 2H16: Phase 2b 2 nd -line SCLC data expected 2H16: Initiate Phase 1 trial with DK049 2H16: Select next drug-conjugate for clinical development 21
23 Financial Summary Balance Sheet (3/31/16) Cash: $68.2M Debt: $25.0M $40M long-term loan secured 2/8/16; Initial tranche of $25M Additional $15M in long-term debt is available at CytRx s option in 2016 subject to R&D milestones Shares Outstanding 68.3M Options Average strike price: $ M Warrants Average strike price: $ M 6.4M expire on Aug 1,
24 Conclusion Aldoxorubicin demonstrated superiority to doxorubicin in a global Phase 2b trial in 1 st -line STS Top-line results from pivotal Phase 3 trial expected in July 2016 Commercial launch in STS planned for 2017 Novel LADR TM technology platform with broad applicability Next generation of LADR TM derived oncology drugs in development including DK049 - IND planned for
Corporate Overview. May 2017 NASDAQ: CYTR
Corporate Overview May 2017 NASDAQ: CYTR CytRx Safe Harbor Statement THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE CERTAIN RISKS AND UNCERTAINTIES. ACTUAL RESULTS COULD DIFFER MATERIALLY
More informationCorporate Overview. February 2018 NASDAQ: CYTR
Corporate Overview February 2018 NASDAQ: CYTR CytRx Safe Harbor Statement THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE CERTAIN RISKS AND UNCERTAINTIES. ACTUAL RESULTS COULD DIFFER
More informationNASDAQ: CYTR FIGHTING CANCER WITH CUTTING EDGE SCIENCE. Corporate Overview. July 2018
NASDAQ: CYTR Corporate Overview July 2018 CytRx Safe Harbor Statement THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE CERTAIN RISKS AND UNCERTAINTIES. ACTUAL RESULTS COULD DIFFER MATERIALLY
More informationIMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics
IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases Rodman & Renshaw 19 th Annual Global Investment Conference Michael R. Garone, Principal Executive Officer and CFO Forward-Looking
More informationRevolutionizing the Treatment of Cancer
Revolutionizing the Treatment of Cancer June 2014 Safe Harbor Statement The statements that follow (including projections and business trends) are forward looking statements. Rexahn's actual results may
More informationIMMUNOMEDICS, INC. November Advanced Antibody-Based Therapeutics. Oncology Autoimmune Diseases
IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases November 2017 Forward-Looking Statements This presentation, in addition to historical information, contains certain
More informationRevolutionizing the Treatment of Cancer
Revolutionizing the Treatment of Cancer January 2014 Safe Harbor Statement The statements that follow (including projections and business trends) are forward looking statements. Rexahn's actual results
More informationIMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics. Jefferies 2014 Global Healthcare Conference Cynthia L. Sullivan, President and CEO
IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases Jefferies 2014 Global Healthcare Conference Cynthia L. Sullivan, President and CEO Forward-Looking Statements This presentation,
More informationRevolutionizing the Treatment of Cancer
Revolutionizing the Treatment of Cancer March 2014 Safe Harbor Statement The statements that follow (including projections and business trends) are forward-looking statements. Rexahn's actual results may
More informationIMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics. Jefferies 2015 Global Healthcare Conference Peter P. Pfreundschuh, VP Finance and CFO
IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases Jefferies 2015 Global Healthcare Conference Peter P. Pfreundschuh, VP Finance and CFO Forward-Looking Statements This
More informationADAPTIMMUNE INVESTOR PRESENTATION. August 2016
ADAPTIMMUNE INVESTOR PRESENTATION August 2016 DISCLAIMER This presentation contains forward-looking statements, as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA),
More informationTrabectedin in ASTS. Le Cesne A, et al. J Clin Oncol. 2018;36(suppl): Abstract
Results of a Prospective Randomized Phase III T-SAR Trial Comparing Trabectedin vs Best Supportive Care (BSC) in Patients With Pretreated Advanced Soft Tissue Sarcoma (ASTS) Abstract 11508 Le Cesne A,
More informationCompany presentation. Claudio Bordignon, Chairman and CEO. Jefferies Global Healthcare Conference New York, 7 June 2012
Company presentation Claudio Bordignon, Chairman and CEO Jefferies Global Healthcare Conference New York, 7 June 2012 Forward-looking statements The presentation contains certain forward-looking statements.
More informationCorporate Presentation May Transforming Immuno-Oncology Using Next-Generation Immune Cell Engagers
Corporate Presentation May 2016 Transforming Immuno-Oncology Using Next-Generation Immune Cell Engagers Forward-looking statements / safe harbor This presentation and the accompanying oral commentary contain
More informationInvestor Call. May 19, Nasdaq: IMGN
Investor Call May 19, 2017 Nasdaq: IMGN Forward-Looking Statements This presentation includes forward-looking statements based on management's current expectations. These statements include, but are not
More informationRevolutionizing the Treatment of Cancer
Revolutionizing the Treatment of Cancer September 2013 Safe Harbor Statement The statements that follow (including projections and business trends) are forward looking statements. Rexahn's actual results
More informationVAL-083: Validated DNA-targeting Agent for Underserved Cancer Patients. September 2018
VAL-083: Validated DNA-targeting Agent for Underserved Cancer Patients September 2018 Forward-Looking Statements Any statements contained in this presentation that do not describe historical facts may
More informationTARGET A BETTER NOW FORWARD-LOOKING STATEMENTS NASDAQ: IMGN. Current as of January 2018
NASDAQ: IMGN TARGET A BETTER NOW Current as of January 2018 FORWARD-LOOKING STATEMENTS This presentation includes forward looking statements based on management's current expectations. These statements
More informationThird Quarter 2015 Earnings Call. November 9, 2015
Third Quarter 2015 Earnings Call November 9, 2015 Forward-Looking Statements All of the statements in this presentation that are not statements of historical facts constitute forward-looking statements
More informationtrabectedin, 0.25 and 1mg powder for concentrate for solution for infusion (Yondelis ) SMC No. (452/08) Pharma Mar S.A. Sociedad Unipersonal
trabectedin, 0.25 and 1mg powder for concentrate for solution for infusion (Yondelis ) SMC No. (452/08) Pharma Mar S.A. Sociedad Unipersonal 08 October 2010 The Scottish Medicines Consortium (SMC) has
More informationPrecision Therapeutics For Hard-To-Treat Cancers
Precision Therapeutics For Hard-To-Treat Cancers George O. Elston, CEO Life Sciences Summit November 2, 2017 1 About Us Precision therapeutics addressing significant unmet medical needs in hard-to-treat
More information33 rd Annual J.P. Morgan Healthcare Conference. January 2015
33 rd Annual J.P. Morgan Healthcare Conference January 2015 Forward-looking Statements This presentation contains forward-looking statements, which express the current beliefs and expectations of management.
More informationCorporate Overview June 2014 Jefferies Healthcare Conference NASDAQ: GLYC
Corporate Overview June 2014 Jefferies Healthcare Conference NASDAQ: GLYC Forward-Looking Statements To the extent that statements contained in this presentation are not descriptions of historical facts
More informationRexahn Pharmaceuticals Overview
Rexahn Pharmaceuticals Overview May 2018 Safe Harbor Statement The statements that follow (including projections and business trends) are forward-looking statements. Rexahn s actual results may differ
More informationOncology Therapeutics without Compromise APRIL 2011
Oncology Therapeutics without Compromise APRIL 2011 Forward Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties, including among other
More informationQ Financial Update November 6, 2018 NASDAQ:FPRX
Q3 2018 Financial Update November 6, 2018 NASDAQ:FPRX 2 Forward-Looking Statements Disclaimer Forward-looking statements contained in this presentation include statements regarding (i) the timing of initiation,
More informationThe legally binding text is the original French version
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 2 April 2008 YONDELIS 0.25 mg, vial containing powder for concentrate for solution for infusion Box containing 1 vial
More informationMerrimack Pharmaceuticals: A Refocused R&D Company January 2017
Merrimack Pharmaceuticals: A Refocused R&D Company January 2017 Forward Looking Statements This presentation contains forward-looking statements of the Company that involve substantial risks and uncertainties.
More informationCorporate Presentation October 2018 Nasdaq: ADXS
Innovations in Immuno-Oncology Corporate Presentation October 2018 Nasdaq: ADXS Forward-Looking Statements This presentation contains forward-looking statements, including, but not limited to, statements
More informationA Fully Integrated Cancer Company.
A Fully Integrated Cancer Company. Jefferies 2015 Healthcare Conference June 2, 2015 Robert Mulroy, President & CEO Forward Looking Statements To the extent that statements contained in this presentation
More informationLonnie Moulder, CEO Leerink Global Healthcare Conference February 12, 2015
Lonnie Moulder, CEO Leerink Global Healthcare Conference February 12, 2015 Safe Harbor Statement Statements made in this presentation about TESARO, Inc. that are not descriptions of historical facts are
More informationCorporate Overview. June 2018 NASDAQ:FPRX
Corporate Overview June 2018 NASDAQ:FPRX Forward-Looking Statements Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of
More informationDisrupting the Cell Cycle to Treat AML and MDS Rodman & Renshaw Conference
CYC 682 Disrupting the Cell Cycle to Treat AML and MDS Rodman & Renshaw Conference September 2014 Disclaimer This presentation contains forward-looking statements within the meaning of the safe harbor
More informationGenta Incorporated. A Multiproduct Late-Stage Oncology Company
Genta Incorporated A Multiproduct Late-Stage Oncology Company This presentation may contain forward-looking statements with respect to business conducted by Genta Incorporated. By their nature, forward-looking
More informationArQule Jefferies Global Healthcare Conference June 2015
ArQule Jefferies Global Healthcare Conference June 2015 1 ArQule Corporate Update Safe Harbor This presentation and other statements by ArQule may contain forward-looking statements within the meaning
More informationNewLink Genetics Corporation
Cantor Fitzgerald Global Healthcare Conference NewLink Genetics Corporation NASDAQ: NLNK September 25, 2017 Forward-Looking Disclaimer This presentation contains forward-looking statements of NewLink that
More informationMarch Corporate Presentation
March 2017 Corporate Presentation Disclaimer This presentation contains forward-looking statements, as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements
More informationJefferies Global Healthcare Conference New York 2014
Jefferies Global Healthcare Conference New York 2014 Disclaimer This document includes only summary information and does not intend to be comprehensive. Facts, figures and opinions contained herein, other
More informationCorporate Presentation September Nasdaq: ADXS
Corporate Presentation September 2018 Nasdaq: ADXS Forward-Looking Statements This presentation contains forward-looking statements, including, but not limited to, statements regarding the ability and
More informationForward-Looking Statements
Current as of November 30, 2017 Nasdaq: IMGN Forward-Looking Statements This presentation includes forward looking statements based on management's current expectations. These statements include, but are
More informationFull Year 2017 Financial Results. February 14, 2018
Full Year 2017 Financial Results February 14, 2018 Agios Conference Call Participants Prepared Remarks Introduction KENDRA ADAMS, Sr. Director, Investor Relations 2018 Vision & Key Milestones DAVID SCHENKEIN,
More informationCorporate Overview May 8, 2014
0 Corporate Overview May 8, 2014 NASDAQ: CRIS Forward Looking Statements This presentation contains statements about Curis future expectations, plans and prospects that constitute forward-looking statements
More informationKaryopharm Reports Second Quarter 2015 Financial Results and Highlights Recent Progress
August 10, 2015 Karyopharm Reports Second Quarter 2015 Financial Results and Highlights Recent Progress - Positive Selinexor Clinical Data Presented across Several Difficult to Treat Cancers - - Provides
More informationJefferies Global Healthcare Conference
Jefferies Global Healthcare Conference June 8, 2017 Nasdaq: IMGN Forward-Looking Statements This presentation includes forward-looking statements based on management's current expectations. These statements
More informationSafe Harbor Statement
Safe Harbor Statement This document may include statements that constitute forward looking statements, which are often characterized by the terms may, believes, expects or anticipates and do not reflect
More informationLeerink Immuno-Oncology Roundtable Conference
Leerink Immuno-Oncology Roundtable Conference September 28, 2017 NASDAQ:FPRX Forward-Looking Statements Disclaimer This presentation contains forward-looking statements within the meaning of the Private
More informationA Fully Integrated Cancer Company.
A Fully Integrated Cancer Company. Jefferies Global Healthcare Conference June 3, 2014 Robert Mulroy, President and CEO Forward Looking Statements To the extent that statements contained in this presentation
More informationDawson James Conference
Dawson James Conference October 2018 Forward-looking Statements Except for historical information, this presentation contains forward-looking statements, which reflect IMV s current expectations regarding
More informationInvestor Presentation
Investor Presentation June 2017 Joe Turgeon President and Chief Operating Officer Safe Harbor Statement This presentation contains forward-looking statements regarding future events and the future performance
More informationCorporate Presentation
Corporate Presentation Leerink Global Healthcare Conference February 14 th -15 th, 2018 C O N F I D E N T I A L a n d P R O P R I E T A R Y Forward Looking Statements / Safe Harbor This presentation contains
More informationBuilding a Premier Oncology Biotech
Corporate Deck Building a Premier Oncology Biotech Dr. Helen Torley, President and CEO November 2018 Forward-Looking Statements All of the statements in this presentation that are not statements of historical
More informationInducing Tumor-Specific Ischemic Necrosis to Enhance the Efficacy of Checkpoint Inhibitors and Chemotherapy
Inducing Tumor-Specific Ischemic Necrosis to Enhance the Efficacy of Checkpoint Inhibitors and Chemotherapy Company Overview, September 2018 Safe Harbor Statement This presentation contains forward-looking
More informationNY-ESO SPEAR T-cells in Synovial Sarcoma
NY-ESO SPEAR T-cells in Synovial Sarcoma ASCO Update June 6, 2017 Disclaimer This presentation contains forward-looking statements, as that term is defined under the Private Securities Litigation Reform
More informationDicerna Pharmaceuticals Overview. Delivering RNAi-Based Breakthrough Therapies
Pharmaceuticals Overview Delivering RNAi-Based Breakthrough Therapies Forward-Looking Statements This information may contain projections and other forward looking statements regarding future events, including
More informationLION. Corporate Presentation June 2016 BIOTECHNOLOGIES. Leadership & Innovation in Oncology
LION BIOTECHNOLOGIES Leadership & Innovation in Oncology Corporate Presentation June 2016 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private
More informationMerck ASCO 2015 Investor Briefing
Merck ASCO 2015 Investor Briefing Forward-Looking Statement This presentation includes forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation
More informationDetermined to realize a future in which people with cancer live longer and better than ever before
Determined to realize a future in which people with cancer live longer and better than ever before 3Q 2018 EARNINGS PRESENTATION NOVEMBER 2018 1 Forward-looking statements disclosure This presentation
More informationDynavax Corporate Presentation
Dynavax Corporate Presentation Forward-Looking Statements This presentation contains forward-looking statements, including statements regarding our HEPLISAV-B TM regulatory submissions, product profile,
More informationScientific Perspectives of Olaratumab Beyond the Approval Indication
Scientific Perspectives of Olaratumab Beyond the Approval Indication William D. Tap, MD Chief, Sarcoma Medical Oncology Service Memorial Sloan Kettering Cancer Center GEIS XVI International Symposium October
More informationAmicus Establishes Gene Therapy Pipeline for Lysosomal Storage Disorders (LSDs) Conference Call and Webcast September 20, 2018
Amicus Establishes Gene Therapy Pipeline for Lysosomal Storage Disorders (LSDs) Conference Call and Webcast September 20, 2018 Introduction 2 Safe Harbor This presentation contains "forward-looking statements"
More informationHighlights of these abstracts are presented below:
PharmaMar announces the presentation of 15 abstracts on Yondelis and Aplidin at the 46 th annual meeting of the American Society of Clinical Oncology (ASCO) Madrid, 9 June 2010: PharmaMar SA (Grupo Zeltia,
More informationActinium Pharmaceuticals, Inc.
, Inc. Actimab-A MRD Consolidation Strategy in MRD+ AML July 10, 2018 1 Disclaimer and Safe Harbor Some of the information presented herein may contain projections or other forward-looking statements regarding
More informationSunesis Pharmaceuticals Reports Second Quarter 2011 Financial Results
Investor and Media Inquiries: David Pitts Argot Partners 212-600-1902 Eric Bjerkholt Sunesis Pharmaceuticals Inc. 650-266-3717 Sunesis Pharmaceuticals Reports Second Quarter 2011 Financial Results SOUTH
More informationGW Pharmaceuticals plc. Investor Presentation August 2014
GW Pharmaceuticals plc Investor Presentation August 2014 Forward Looking Statements and Disclaimer This presentation contains forward-looking statements. Some of the matters discussed concerning our operations
More informationCorporate Presentation November Transforming Immuno-Oncology Using Next-Generation Immune Cell Engagers
Corporate Presentation November 2015 Transforming Immuno-Oncology Using Next-Generation Immune Cell Engagers Forward-looking statements / safe harbor This presentation and the accompanying oral commentary
More informationDetermined to realize a future in which people with cancer live longer and better than ever before
Determined to realize a future in which people with cancer live longer and better than ever before 4Q 2016 EARNINGS PRESENTATION MARCH 2017 1 Forward-looking statements disclosure This presentation contains
More informationTargeting and Treating Cancer
Targeting and Treating Cancer Mark R. Baker, Chief Executive Officer Jefferies Healthcare Conference June 2015 Disclosure Notice This presentation may contain projections and other forward-looking statements
More informationBuilding a Premier Oncology Biotech
Building a Premier Oncology Biotech August 208 Forward-Looking Statements All of the statements in this presentation that are not statements of historical facts constitute forward-looking statements within
More informationBreakthrough Cancer Therapies: Directing the Immune System to Eliminate Tumor Cells. Corporate Presentation June 2015
Breakthrough Cancer Therapies: Directing the Immune System to Eliminate Tumor Cells Corporate Presentation June 2015 Forward-looking statements / safe harbor This presentation and the accompanying oral
More informationCORPORATE PRESENTATION
CORPORATE PRESENTATION June 2017 FORWARD LOOKING SAFE HARBOR STATEMENT This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
More informationDisrupting the Cell Cycle to Treat AML, MDS and other Cancers
CYC 682 Disrupting the Cell Cycle to Treat AML, MDS and other Cancers February 2015 Disclaimer This presentation contains forward-looking statements within the meaning of the safe harbor provisions of
More informationDelcath Investor Presentation (OTCQB: DCTH)
Delcath Investor Presentation (OTCQB: DCTH) December 2018 1 DELCATH SYSTEMS, INC Forward-looking Statements This presentation contains forward-looking statements, within the meaning of the federal securities
More informationUse of Single-Arm Cohorts/Trials to Demonstrate Clinical Benefit for Breakthrough Therapies. Eric H. Rubin, MD Merck Research Laboratories
Use of Single-Arm Cohorts/Trials to Demonstrate Clinical Benefit for Breakthrough Therapies Eric H. Rubin, MD Merck Research Laboratories Outline Pembrolizumab P001 study - example of multiple expansion
More informationARIAD Pharmaceuticals, Inc.
ARIAD Pharmaceuticals, Inc. June 8, 2016 David Sachs Non-small cell lung cancer 1 ARIAD clinical trial patient Some of the statements in this presentation constitute forward looking statements under the
More informationIdenix Pharmaceuticals Building a Leading Antiviral Franchise. Cowen & Company 27 th Annual Healthcare Conference March 13, 2007 Boston
Idenix Pharmaceuticals Building a Leading Antiviral Franchise Cowen & Company 27 th Annual Healthcare Conference March 13, 2007 Boston Safe Harbor This presentation includes forward-looking statements
More informationBusiness Update & Financial Results for Q1 2018
Business Update & Financial Results for Q1 2018 May 15, 2018 Disclaimer The statements made in this presentation may include forward-looking statements regarding the future operations of ERYTECH Pharma
More informationJune IMMUNE DESIGN The in vivo generation of cytotoxic CD8 T cells (CTLs)
June 2015 IMMUNE DESIGN The in vivo generation of cytotoxic CD8 T cells (CTLs) 1 Forward-looking Statements This presentation contains forward-looking statements with respect to, among other things, our
More informationREWRITING CANCER TREATMENT THROUGH EPIGENETIC MEDICINES
REWRITING CANCER TREATMENT THROUGH EPIGENETIC MEDICINES May 18, 2017 Molecularly Defined Solid Tumor Program Update FORWARD-LOOKING STATEMENTS Any statements in this press release about future expectations,
More informationForward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements, including statements related to Seattle Genetics corporate priorities, financial guidance and anticipated upcoming activities,
More informationInfinity Highlights Promising Preclinical Hedgehog Data and Announces First Quarter Financial Results
Infinity Highlights Promising Preclinical Hedgehog Data and Announces First Quarter Financial Results Heat Shock Protein 90 Program Continues to Advance Toward Potential Registration Trial CAMBRIDGE, Mass.,
More informationTranslating cancer biology into medicines Noble Capital Markets Conference NASDAQ CYCC - January 30, 2018
CYC 682 Translating cancer biology into medicines Noble Capital Markets Conference NASDAQ CYCC - January 30, 2018 Disclaimer This presentation contains forward-looking statements within the meaning of
More information9M RESULTS 2014 CONFERENCE CALL DR. MATTHIAS SCHROFF, CEO
9M RESULTS 2014 CONFERENCE CALL DR. MATTHIAS SCHROFF, CEO BERLIN, 13 NOVEMBER, 2014 Disclaimer Certain statements in this presentation contain formulations or terms referring to the future or future developments,
More informationProstate Cancer Panel. June 2018
Prostate Cancer Panel June 2018 Forward Looking Statements Certain of the statements made in this presentation are forward looking, such as those, among others, relating to future spending, future cash
More informationDetermined to realize a future in which people with cancer live longer and better than ever before 4Q18 EARNINGS PRESENTATION MARCH 2019
Determined to realize a future in which people with cancer live longer and better than ever before 4Q18 EARNINGS PRESENTATION MARCH 2019 Forward-looking statements disclosure This presentation contains
More informationJuly, ArQule, Inc.
July, 2012 Safe Harbor This presentation and other statements by ArQule may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to clinical
More informationNewLink Genetics Corporation
Cantor Fitzgerald 2018 Global Healthcare Conference NewLink Genetics Corporation NASDAQ: NLNK October 3, 2018 Cautionary Note Regarding Forward-Looking Statements This presentation contains forward-looking
More information2016 Year-End Results and Conference Call. March 14, 2017
2016 Year-End Results and Conference Call March 14, 2017 Forward Looking Statement This communication contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform
More informationMOLOGEN AG Jefferies 2014 London Healthcare Conference
Jefferies 2014 London Healthcare Conference Dr. Matthias Schroff Chief Executive Officer London 20 November 2014 V1-6 Disclaimer Certain statements in this presentation contain formulations or terms referring
More informationMOLOGEN AG. Pioneering Immune Therapy. Annual Results Analysts Call March 25, 2014
Pioneering Immune Therapy Annual Results 2013 Analysts Call March 25, 2014 Disclaimer Certain statements in this presentation contain formulations or terms referring to the future or future developments,
More informationAVEO and Astellas Announce TAURUS Patient Preference Clinical Study Comparing Tivozanib with Sunitinib in First-Line Kidney Cancer
FOR IMMEDIATE RELEASE AVEO and Astellas Announce TAURUS Patient Preference Clinical Study Comparing Tivozanib with Sunitinib in First-Line Kidney Cancer Study designed to build upon safety profile demonstrated
More informationCorporate Presentation: Jefferies Global Healthcare Conference June 7, 2018
Corporate Presentation: Jefferies Global Healthcare Conference June 7, 2018 2018 CytomX Therapeutics, Inc. 1 Forward Looking Statements Special Note Regarding Forward-Looking Statements This presentation
More informationReview Article A Systematic Literature Review of Adverse Events Associated with Systemic Treatments Used in Advanced Soft Tissue Sarcoma
Sarcoma Volume 2016, Article ID 3597609, 13 pages http://dx.doi.org/10.1155/2016/3597609 Review Article A Systematic Literature Review of Adverse Events Associated with Systemic Treatments Used in Advanced
More informationAVEO and Astellas Report Final Overall Survival Results from TIVO-1
AVEO and Astellas Report Final Overall Survival Results from TIVO-1 - Median Overall Survival of 28.8 Months Reported for Tivozanib in Patients with Advanced Kidney Cancer - CAMBRIDGE, Mass. and TOKYO,
More informationSpectrum Pharmaceuticals
Spectrum Pharmaceuticals Joe Turgeon President and CEO June 2018 Investor Presentation 1 Safe Harbor Statement This presentation contains forward looking statements regarding future events and the future
More informationCorporate Overview. June 2017 NASDAQ:FPRX
Corporate Overview June 2017 NASDAQ:FPRX Forward-Looking Statements Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of
More informationCORPORATE PRESENTATION 2015
CORPORATE PRESENTATION 2015 DISCLAIMER This document includes only summary information and does not intend to be comprehensive. Facts, figures and opinions contained herein, other than historical, are
More informationSAVARA CORPORATE PRESENTATION (NASDAQ: SVRA) NOVEMBER 2018
SAVARA CORPORATE PRESENTATION (NASDAQ: SVRA) NOVEMBER 2018 SAFE HARBOR STATEMENT Savara Inc. ( Savara or the Company ) cautions you that statements in this presentation that are not a description of historical
More informationHALOZYME REPORTS SECOND QUARTER 2018 RESULTS
Contacts: Robert H. Uhl Managing Director Westwicke Partners, LLC 858-356-5932 robert.uhl@westwicke.com Laurie Stelzer 858-704-8222 ir@halozyme.com FOR IMMEDIATE RELEASE HALOZYME REPORTS SECOND QUARTER
More information2008 Bank of America Health Care Conference May 2008
2008 Bank of America Health Care Conference May 2008 NASDAQ: ALTH -1- Safe Harbor Statement This presentation contains forward-looking statements that are made pursuant to the safe harbor provisions of
More informationBreathtaking science. Developing respiratory drugs to improve health and quality of life. H.C. Wainwright Global Life Sciences Conference April 2018
Breathtaking science Developing respiratory drugs to improve health and quality of life H.C. Wainwright Global Life Sciences Conference April 2018 www.veronapharma.com Forward-Looking Statements This presentation
More information